• Minaris Regenerative Medicine and TFBS Announce Strategic Partnership to Advance Cell and Gene Therapy

  2024-10-02 Minaris Regenerative Medicine and TFBS Announce Strategic Partnership to Advance Cell and Gene Therapy Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) mainly in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing the one-stop-shop solutions. Learn more

• 基米與啟弘簽MOU 開啟細胞及基因治療檢測新局

  2024-08-15 基米與啟弘簽MOU 開啟細胞及基因治療檢測新局 基龍米克斯生物科技股份有限公司（以下簡稱“基米”，股票代碼：4195）與啟弘生物科技股份有限公司（以下簡稱“啟弘”，股票代碼：6939）今（15）日宣布簽署合作備忘錄，將結合雙方優勢，打造強化細胞及基因治療（CGT）產品的次世代基因定序（NGS）檢測平台，未來也將共同進行推廣，搶攻龐大再生醫療市場商機。 Learn more

• President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA

  2024-05-08 President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA Learn more

• 啟弘生技成功搶進日本病毒載體市場 獲選為日本三重大學及Bio Como的製造夥伴，共同推動呼吸道融合病毒疫苗的臨床發展

  2024-04-25 啟弘生技成功搶進日本病毒載體市場 獲選為日本三重大學及Bio Como的製造夥伴，共同推動呼吸道融合病毒疫苗的臨床發展 近年來，全球面臨著各種新興感染症的挑戰，為了有效應對這些威脅，日本BioComo公司與三重大學攜手合作，經日本政府醫療政策設立之Japan Agency for Medical Research and Development（AMED）的支持下，致力於研發新型病毒載體技術以應用於新興感染症疫苗平台。啟弘生技獲選為日本BioComo公司與三重大學的合作案之病毒載體研發製造夥伴，將共同推動呼吸道融合病毒（RSV）疫苗的臨床發展。 Learn more

• TFBS Brochure

  2023-04-07 TFBS Brochure Learn more